Talaris Therapeutics, Inc. (TALS): Price and Financial Metrics
TALS Price/Volume Stats
| Current price | $27.20 | 52-week high | $27.95 |
| Prev. close | $2.74 | 52-week low | $0.89 |
| Day low | $26.90 | Volume | 30,520 |
| Day high | $27.95 | Avg. volume | 386,531 |
| 50-day MA | $2.83 | Dividend yield | N/A |
| 200-day MA | $2.41 | Market Cap | 1.16B |
TALS Stock Price Chart Interactive Chart >
Talaris Therapeutics, Inc. (TALS) Company Bio
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
TALS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -82.05% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -93.33% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...